Brighton Jones LLC
RXRX icon

Brighton Jones LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Brighton Jones LLC’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.1K Buy
26,733
+602
+2% +$2K ﹤0.01% 1311
2026
Q1 		$80.2K Buy
+26,131
New +$101K ﹤0.01% 1141
2025
Q4 		– Sell
-27,727
Closed -$135K – 766
2025
Q3 		$135K Sell
27,727
-1,582
-5% -$8.31K ﹤0.01% 983
2025
Q2 		$148K Buy
29,309
+8,156
+39% +$40.1K ﹤0.01% 879
2025
Q1 		$112K Buy
21,153
+892
+4% +$6.5K ﹤0.01% 676
2024
Q4 		$137K Buy
20,261
+6,699
+49% +$45K ﹤0.01% 659
2024
Q3 		$89.4K Buy
+13,562
New +$97.2K ﹤0.01% 562

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brighton Jones LLC's RXRX Position: Q2 2026 in Review

Brighton Jones LLC increased its Recursion Pharmaceuticals (RXRX) stake by 2.3% in Q2 2026, buying an estimated $2K and bringing the position to 26,733 shares worth $98.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

Brighton Jones LLC first reported a position in RXRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $148K in Q2 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Brighton Jones LLC held 26,733 shares of Recursion Pharmaceuticals worth $98.1K as of Q2 2026.
  • Brighton Jones LLC bought 602 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1311 holding.
  • Brighton Jones LLC first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Brighton Jones LLC's Recursion Pharmaceuticals position peaked at $148K in Q2 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.